With the addition of adiponectin’s potential as a biomarker for risk monitoring after birth, targeted prevention of T2D in LBW subjects may include both antenatal and postnatal prevention and risk mitigation efforts. Here, ADIPOQ is linked to type 2 diabetes mellitus.